Overview

Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder

Status:
Completed
Trial end date:
2001-10-01
Target enrollment:
0
Participant gender:
Female
Summary
Our study aims at contributing to a valid appraisal of the magnitude of naltrexone efficacy as an antidissociative agent by using a double-blind randomized controlled trial.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Central Institute of Mental Health, Mannheim
Collaborator:
University of Freiburg
Treatments:
Naltrexone
Criteria
Inclusion Criteria:

- Diagnosis of BPD according to DSM-IV

- DES score ≥ 18

- Female gender

- Age between 18 and 50 years

Exclusion Criteria:

- Lifetime diagnosis of schizophrenia, psychotic or delusional disorder

- Current major depressive episode

- Lifetime diagnosis opioid dependence

- Current diagnosis opioid abuse

- Liver insufficiency or hepatitis

- Other major medical or neurological medical condition

- Pregnancy or lactation

- Psychotropic medication within two weeks before and during the trial (fluoxetine 4
weeks, lithium 8 weeks)

- Concomitant treatment with opioid analgetics

- Hypersensitivity to naltrexone